Antiepileptic drugs and the liver;Antiepilepticos e higado

Revista de Neurologia

Volumn 30, Issue SUPPL. 1, 2000, Pages

  Adin J ^a   Gutierrez Rubio F ^a   Armijo, J A ^a  

^a HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

Author keywords

Active metabolites; Antiepileptic drugs; CYP; Cytochrome P 450; Enzyme induction; Enzyme inhibition; Glucuronidation; Liver metabolism; Microsome oxidation; Pharmacokinetic interactions; Toxicity; Uridindiphosphoglucuronosyltransferase

Indexed keywords

ANTICONVULSIVE AGENT; CYTOCHROME P450; HEXOSE 1 PHOSPHATE URIDYLYLTRANSFERASE; ISOENZYME;

CONFERENCE PAPER; DRUG GLUCURONIDATION; DRUG METABOLISM; ENZYME INDUCTION; ENZYME INHIBITION; EPILEPSY; LIVER FUNCTION; LIVER METABOLISM; LIVER MICROSOME; LIVER TOXICITY; ENZYMOLOGY; HUMAN; LIVER; METABOLISM; REVIEW;

ANTICONVULSANTS; CYTOCHROME P-450 ENZYME SYSTEM; EPILEPSY; HUMANS; ISOENZYMES; LIVER; UDPGLUCOSE-HEXOSE-1-PHOSPHATE URIDYLYLTRANSFERASE;

EID: 0033915057     PISSN: 02100010     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (32)

1. Perucca E, Richens A. General principles: biotransformation. In Levy RH, Mattson RH, Meldrum BS, eds. Antiepileptic drugs. 4 ed. New York: Raven Press; 1995. p. 31-50.
2. Armijo JA. Farmacocinética: absorción, distribución y eliminación de los fármacos. En Rodés J, Guardia J, eds. Medicina interna. Barcelona: Masson; 1997. p. 760-78.
3. Nelson DR, Kanataki T, Waxman DJ, Guengerich FP, Estrabrook RW, Feyereisen R, et al. The P450 superfamily: update on new sequences, gene mapping, accession numbers, early trivial names of enzymes, and nomenclature. DNA Cell Biol 1993; 12: 1-51.
4. Benet LZ, Kroetz DL, Sheiner LB. Farmacocinética: dinámica de la absorción, distribución y eliminación de los fármacos. En Hardman JG, Limbird LE, Molinoff PB, Ruddon RW, Goodman-Gilman A, eds. Goodman and Gilman: las bases farmacológicas de la terapéutica. 9 ed. Madrid: McGraw-Hill-Interamericana; 1996. p. 2-29.
5. Mackenzie PI, Owens IS. Cleavage of nascent UDP glucuronosyltransferase from rat liver by dog pancreatic microsomes. Biochem Biophys Res Commun 1984; 122: 1441-9.
6. De Wildt SN, Kearns GL, Leeder JS, van der Anker JN. Glucuronidation in humans. Pharmacogenetic and developmental aspects. Clin Pharmacokinet 1999; 36: 439-52.
7. Mackenzie PI, Owens IS, Burchell B, Bock KW, Bairoch A, Belanger A, et al. The UDP glycosyltransferase gene superfamily: recommended nomenclature update based on evolutionary divergence. Pharmacogenetics 1997; 7: 255-69.
8. Debinski HS, Mackenzie PI, Lee CS, Mashford ML, Danks JA, Tephly TR, et al. UDP glucuronosyltransferase in the cirrhotic rat liver. J Gastroenterol Hepatol 1996; 11: 373-9.
9. Furlan V, Demirdjian S, Bourdon O, Magdalou J, Taburet AM. Glucuronidation of drugs by hepatic microsomes derived from healthy and cirrhotic human livers. J Pharmacol Exp Ther 1999; 289: 1169-75.
10. Green MD, Tephly TR. Glucuronidation of amine substrates by purified and expressed UDP-glucuronosyltransferase proteins. Drug Metab Dispos 1998; 26: 860-7.
11. Armijo JA, Adín J. Bases farmacocinéticas para la asociación de antiepilépticos. Rev Neurol 1997; 25 (Supl 4): S382-95.
12. Willmore LJ. The effect of age on pharmacokinetics of antiepileptic drugs. Epilepsia 1995; 36 (Suppl 5): S14-21.
13. Lau AH, Gustavson LE, Sperelakis R, Lam NP, El-Shourbagy T, Qian JX, et al. Pharmacokinetics and safety of tiagabine in subjects with various degrees of hepatic function. Epilepsia 1997; 38: 445-51.
14. Knowles SR, Shapiro LE, Shear NH. Anticonvulsant hypersensitivity syndrome: incidence, prevention and management. Drug Saf 1999; 21: 489-501.
15. Lindhout D, Omtzigt JGC. Teratogenic effects of antiepileptic drugs: implications for the management of epilepsy in women of childbearing age. Epilepsia 1994; 35 (Suppl 4): S19-28.
16. Dickinson RG, Eadie MJ, Vajda FJE. Carbamazepine. In Eadie MG, Vajda FJE, eds. Antiepileptic drugs: pharmacology and therapeutics. Berlin: Springer; 1999. p. 267-318.
17. Faigle JW, Feldman KF. Carbamazepine: chemistry and biotransformation. In Levy RH, Mattson RH, Meldrum BS, eds. Antiepileptic drugs. 4 ed. New York: Raven Press; 1995. p. 499-513.
18. Anderson GD. A mechanistic approach to antiepileptic drug interactions. Ann Pharmacother 1998; 32: 554-63.
19. Kilpatrick C. Benzodiazepines. In Eadie MG, Vajda FJE, eds. Antiepileptic drugs: pharmacology and therapeutics. Berlin: Springer; 1999. p. 395-424.
20. Patsalos PN. Anticonvulsant combinations and interactions. In Eadie MG, Vajda FJE, eds. Antiepileptic drugs: pharmacology and therapeutics. Berlin: Springer; 1999. p. 553-88.
21. Eadie MJ, Vajda FJE. Older anticonvulsants continuing in use but with limited advance in knowledge. In Eadie MG, Vajda FJE, eds. Antiepileptic drugs: pharmacology and therapeutics. Berlin: Springer; 1999. p. 189-228.
22. Kutt H, Harden CL. Phenytoin and congeners. In Eadie MG, Vajda FJE, eds. Antiepileptic drugs: pharmacology and therapeutics. Berlin: Springer; 1999. p. 229-66.
23. Shen DD, Levy RH. Valproate. In Eadie MG, Vajda FJE, eds. Antiepileptic drugs: pharmacology and therapeutics. Berlin: Springer; 1999. p. 359-74.
24. Baillie TA, Sheffels PR. Valproic acid: chemistry and biotransformation. In Levy RH, Mattson RH, Meldrum BS, eds. Antiepileptic drugs. 4 ed. New York: Raven Press; 1995. p. 589-604.
25. Hooper WD, Franklin ME, Glue P, Banfield, CR, Radwanski E, McLaughlin ME, et al. Effect of felbamate on valproic acid disposition in healthy volunteers: inhibition of beta oxidation. Epilepsia 1996; 37: 91-7.
26. Theodore WH. Felbamate. In Eadie MG, Vajda FJE, eds. Antiepileptic drugs: pharmacology and therapeutics. Berlin: Springer; 1999. p. 499-514.
27. Walker MC, Sander JWAS. Lamotrigine. In Eadie MG, Vajda FJE, eds. Antiepileptic drugs: pharmacology and therapeutics. Berlin: Springer; 1999. p. 331-58.
28. Armijo JA, Bravo J, Cuadrado A, Herranz JL. Lamotrigine serum concentration-to-dose ratio: influence of age and concomitant antiepileptic drugs and dosage implications. Ther Drug Monit 1999; 21: 182-90.
29. Ben-Menachem E. Vigabatrin. In Eadie MG, Vajda FJE, eds. Antiepileptic drugs: pharmacology and therapeutics. Berlin: Springer; 1999. p. 375-94.
30. Heaney D, Shorvon S. Topiramate. In Eadie MG, Vajda FJE, eds. Antiepileptic drugs: pharmacology and therapeutics. Berlin: Springer; 1999. p. 465-84.
31. Riva R, Albani F, Contin M, Baruzzi A. Pharmacokinetic interactions between antiepileptic drugs: clinical considerations. Clin Pharmacokinet 1996; 31: 470-93.
32. Tanaka E. Clinically significant pharmacokinetic drug interactions between antiepileptic drugs. J Clin Pharm Ther 1999; 24: 87-92.